{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.159","value":"5.70"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Week 48"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.154","value":"8.66"},{"groupId":"OG001","spread":"9.807","value":"14.06"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"72"}],"units":"Participants"}],"title":"Week 112"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.067","value":"9.28"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Week 132"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.473","value":"10.32"},{"groupId":"OG001","spread":"10.210","value":"14.96"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"65"}],"units":"Participants"}],"title":"Week 196"}],"denoms":[{"counts":[{"groupId":"OG000","value":"116"},{"groupId":"OG001","value":"93"}],"units":"Participants"}],"description":"PK samples were collected for those patients treated with pasireotide LAR in the core study and who continued on pasireotide LAR in the extension phase. PK samples were collected before the injection of pasireotide LAR only at weeks 112 and 196. PK samples were also collected at weeks 48 and 132 only for all patients treated with octreotide LAR 30 mg or lanreotide ATG 120 mg in the core study who started treatment with pasireotide LAR in the extension study.\n\nBlood samples (2.5 mL each sample) were collected to yield 1-mL plasma for analysis of pasireotide LAR oncentration.","dispersionType":"Standard Deviation","groups":[{"description":"Supplied in blinded fashion as 20 and 40 mg powder in vials and 2 mL vehicle in ampoule (for reconstitution) for intramuscular administration every 28 days","id":"OG000","title":"Pasireotide LAR 40 mg"},{"description":"Supplied in blinded fashion as 20 and 40 mg powder in vials and 2 mL vehicle in ampoule (for reconstitution) for intramuscular administration every 28 days","id":"OG001","title":"Pasireotide LAR 60 mg"}],"paramType":"MEAN","populationDescription":"Available data for analysis varies at visits","reportingStatus":"POSTED","timeFrame":"Extension baseline up to approximately 196 weeks","title":"Summary of Pasireotide Trough Concentrations in Acromegaly Patients Following Monthly i.m. Injections of Pasireotide LAR by Incident Dose From Start of Extension Phase up to Week 196 of the Extension Phase (PK Set)","type":"SECONDARY","unitOfMeasure":"mL"}